繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 上市新药 >> COSENTYX(secukinumab)injection

COSENTYX(secukinumab)injection

2015-02-08 15:07:03  作者:新特药房  来源:互联网  浏览次数:1257  文字大小:【】【】【
简介: 单抗药物Cosentyx(secukinumab,曾用名AIN457) -2015年获批上市,成为首个IL-17阻断剂2015年1月21日,美国食品和药品监管局(FDA)批准Cosentyx (secukinumab)治疗有中度至严重斑块性银屑病成年。银屑病是一 ...

单抗药物Cosentyx(secukinumab,曾用名AIN457) -2015年获批上市,成为首个IL-17阻断剂
2015年1月21日,美国食品和药品监管局(FDA)批准Cosentyx (secukinumab)治疗有中度至严重斑块性银屑病成年。
银屑病是一种皮肤情况致皮肤发红和刺激斑点块。银屑病是一种自身免疫疾病,和在有疾病家族史患者中更常发生,和在年龄15和35人们间大多数往往良性。银屑病的最常见形式是斑块性银屑病,其中患者发生厚,有小薄片红皮肤,银白色的斑块被称为鳞。
Cosentyx的活性成分是依那西普[secukinumab]。依那西普是一种抗体结合至一种涉及炎症中的蛋白(白介素(IL)-17A)。通过结合至IL-17A,依那西普阻止它结合至其受体,和抑制其触发在斑块性银屑病发展中起作用的炎症反应。
Cosentyx是在皮下注射给予。它意向为被选患者全身治疗(在通过口或注射后利用物质经血流旅行治疗),光治疗(紫外线治疗)或两者的联合。
FDA的药品评价和研究中心药物评价III室副主任Amy Egan, M.D., M.P.H.,说:“斑块性银屑病可能致患者显著皮肤刺激和不适,所以重要的是患者可得到各种各样治疗选择。”
在四项临床试验总共2,403例有斑块性银屑病参加者是为光治疗或全身治疗的被选者中确定Cosentyx的安全性和有效性。参加者被随机赋予至接受Cosentyx或一种安慰剂。结构显示 Cosentyx比安慰剂实现更大的临床反应,通过评分皮肤银屑病变化的程度,性质和严重程度评估皮肤清除或几乎清除。
Cosentyx正在被批准有一个用药指南告知患者,因为Cosentyx是一种药物影响免疫系统,患者可能有更大风险获得感染。曾报道使用Cosentyx严重过敏反应。在有某种慢性感染或复发性感染病史患者,和在有活动性克罗恩病[Crohn’s Disease]患者中当考虑使用Cosentyx时应谨慎行事。最常见副作用包括腹泻和上呼吸道感染。
Cosentyx由总部新泽西东汉诺威Novartis Pharmaceuticals Corporation上市。
COSENTYX- secukinumab injection
Novartis Pharmaceuticals Corporation


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use COSENTYX safely and effectively. See full prescribing information for COSENTYX.
COSENTYXTM (secukinumab) injection, for subcutaneous use
COSENTYXTM (secukinumab) for injection, for subcutaneous use
Initial U.S. Approval: 2015
INDICATIONS AND USAGE
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. (1)
DOSAGE AND ADMINISTRATION
•Recommended dose is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable. (2.1)
•See Full Prescribing Information for preparation of the Sensoready® pen and prefilled syringe. (2.3)
•Reconstitute COSENTYX lyophilized powder in a vial with Sterile Water for Injection. Reconstitution should be performed by a healthcare provider. (2.4)
DOSAGE FORMS AND STRENGTHS
•Injection: 150 mg/mL solution in a single-use Sensoready® pen (3)
•Injection: 150 mg/mL solution in a single-use prefilled syringe (3)
•For Injection: 150 mg, lyophilized powder in a single-use vial for reconstitution for healthcare professional use only (3)
CONTRAINDICATIONS
Serious hypersensitivity reaction to secukinumab or to any of the excipients. (4)
WARNINGS AND PRECAUTIONS
•Infections: Serious infections have occurred. Caution should be exercised when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue COSENTYX until the infection resolves. (5.1)
•Tuberculosis (TB): Prior to initiating treatment with COSENTYX, evaluate for TB. (5.2)
•Crohn’s Disease: Exacerbations observed in clinical trials. Caution should be exercised when prescribing COSENTYX to patients with active Crohn’s disease. (5.3)
•Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy. (5.4)
ADVERSE REACTIONS
Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
•Live Vaccines: Live vaccines should not be given with COSENTYX. (5.6, 7.1)
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 1/2015
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
COSENTYXTM is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
The recommended dose is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg.
For some patients, a dose of 150 mg may be acceptable.
2.2 Important Administration Instructions
There are three presentations for COSENTYX (i.e., Sensoready pen, prefilled syringe, and lyophilized powder in vial for reconstitution). The COSENTYX “Instructions for Use” for each presentation contains more detailed instructions on the preparation and administration of COSENTYX [see Instructions for Use].
COSENTYX is intended for use under the guidance and supervision of a physician. Patients may self-inject after proper training in subcutaneous injection technique using the Sensoready pen or prefilled syringe and when deemed appropriate. The lyophilized powder for reconstitution is for healthcare provider use only. Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of COSENTYX in the upper, outer arm may be performed by a caregiver or healthcare provider.
2.3 Preparation for Use of COSENTYX Sensoready® Pen and Prefilled Syringe
Before injection, remove COSENTYX Sensoready pen or COSENTYX prefilled syringe from the refrigerator and allow COSENTYX to reach room temperature (15 to 30 minutes) without removing the needle cap.
The removable cap of the COSENTYX Sensoready pen and the COSENTYX prefilled syringe contains natural rubber latex and should not be handled by latex-sensitive individuals [see Warnings and Precautions (5.5)].
Inspect COSENTYX visually for particulate matter and discoloration prior to administration. COSENTYX injection is a clear to slightly opalescent, colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy. COSENTYX does not contain preservatives; therefore, administer the Sensoready pen or prefilled syringe within 1 hour after removal from the refrigerator. Discard any unused product remaining in the Sensoready pen or prefilled syringe.
2.4 Reconstitution and Preparation of COSENTYX Lyophilized Powder
COSENTYX lyophilized powder should be prepared and reconstituted with Sterile Water for Injection by a trained healthcare provider using aseptic technique and without interruption. The preparation time from piercing the stopper until end of reconstitution on average takes 20 minutes and should not exceed 90 minutes.
a) Remove the vial of COSENTYX lyophilized powder from the refrigerator and allow to stand for 15 to 30 minutes to reach room temperature. Ensure the Sterile Water for Injection is at room temperature.
b) Slowly inject 1 mL of Sterile Water for Injection into the vial containing COSENTYX lyophilized powder and direct the stream of Sterile Water for Injection onto the lyophilized powder.
c) Tilt the vial at an angle of approximately 45 degrees and gently rotate between the fingertips for approximately 1 minute. Do not shake or invert the vial.
d) Allow the vial to stand for about 10 minutes at room temperature to allow for dissolution. Note that foaming may occur.
e) Tilt the vial at an angle of approximately 45 degrees and gently rotate between the fingertips for approximately 1 minute. Do not shake or invert the vial.
f) Allow the vial to stand undisturbed at room temperature for approximately 5 minutes. The reconstituted COSENTYX solution should be essentially free of visible particles, clear to opalescent, and colorless to slightly yellow. Do not use if the lyophilized powder has not fully dissolved or if the liquid contains visible particles, is cloudy or discolored.
g) Prepare the required number of vials (1 vial for the 150 mg dose or 2 vials for the 300 mg dose).
h) The COSENTYX reconstituted solution contains 150 mg of secukinumab in 1 mL of solution. After reconstitution, use the solution immediately or store in the refrigerator at 2ºC to 8ºC (36ºF to 46ºF) for up to 24 hours. Do not freeze.
i) If stored at 2ºC to 8ºC (36ºF to 46ºF), allow the reconstituted COSENTYX solution to reach room temperature (15 to 30 minutes) before administration. COSENTYX does not contain preservatives; therefore, administer within 1 hour after removal from 2ºC to 8ºC (36ºF to 46ºF) storage.
3 DOSAGE FORMS AND STRENGTHS
•Injection: 150 mg/mL solution in a single-use Sensoready pen
•Injection: 150 mg/mL solution in a single-use prefilled syringe
•For Injection: 150 mg, lyophilized powder in a single-use vial for reconstitution (for healthcare professional use only)
4 CONTRAINDICATIONS
COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients [see Warnings and Precautions (5.4)].
5 WARNINGS AND PRECAUTIONS
5.1 Infections
COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX-treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. The incidence of some types of infections appeared to be dose-dependent in clinical studies [see Adverse Reactions (6.1)].
Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.
Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.
5.2 Pre-treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.
5.3 Exacerbations of Crohn’s Disease
Exercise caution when prescribing COSENTYX to patients with active Crohn’s disease, as exacerbations of Crohn’s disease, in some cases serious, were observed in COSENTYX-treated patients during clinical trials. Patients who are treated with COSENTYX and have active Crohn’s disease should be monitored closely [see Adverse Reactions (6.1)].
5.4 Hypersensitivity Reactions
Anaphylaxis and cases of urticaria occurred in COSENTYX-treated patients in the clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated [see Adverse Reactions (6.1)].
5.5 Risk of Hypersensitivity in Latex-sensitive Individuals
The removable cap of the COSENTYX Sensoready pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.
5.6 Vaccinations
Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.
Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.
6 ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail elsewhere in the labeling:
•Infections [see Warnings and Precautions (5.1)]
•Exacerbations of Crohn’s Disease [see Warnings and Precautions (5.3)]
•Hypersensitivity Reactions [see Warnings and Precautions (5.4)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 3430 plaque psoriasis subjects were treated with COSENTYX in controlled and uncontrolled clinical trials. Of these, 1641 subjects were exposed for at least 1 year.
Four placebo-controlled phase 3 trials in plaque psoriasis subjects were pooled to evaluate the safety of COSENTYX in comparison to placebo up to 12 weeks after treatment initiation, in Trials 1, 2, 3, and 4. In total, 2077 subjects were evaluated (691 to COSENTYX 300 mg group, 692 to COSENTYX 150 mg group, and 694 to placebo group) [see Clinical Studies (14)].
Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the COSENTYX groups than the placebo group during the 12-week placebo-controlled period of the placebo-controlled trials.
Table 1 Adverse Reactions Reported by Greater Than 1% of Subjects with Plaque Psoriasis Through Week 12 in Trials 1, 2, 3, and 4

COSENTYX
Adverse Reactions 300 mg
(N=691)
n (%)
150 mg
(N=692)
n (%)
Placebo
(N=694)
n (%)
Nasopharyngitis 79 (11.4) 85 (12.3) 60 (8.6)
Diarrhea 28 (4.1) 18 (2.6) 10 (1.4)
Upper respiratory tract infection 17 (2.5) 22 (3.2) 5 (0.7)
Rhinitis 10 (1.4) 10 (1.4) 5 (0.7)
Oral herpes 9 (1.3) 1 (0.1) 2 (0.3)
Pharyngitis 8 (1.2) 7 (1.0) 0 (0)
Urticaria 4 (0.6) 8 (1.2) 1 (0.1)
Rhinorrhea 8 (1.2) 2 (0.3) 1 (0.1)
Adverse reactions that occurred at rates less than 1% in the placebo-controlled period of Trials 1, 2, 3, and 4 through Week 12 included: sinusitis, tinea pedis, conjunctivitis, tonsillitis, oral candidiasis, impetigo, otitis media, otitis externa, inflammatory bowel disease, increased liver transaminases and neutropenia.
Infections
In the placebo-controlled period of the clinical trials in plaque psoriasis (a total of 1382 subjects treated with COSENTYX and 694 subjects treated with placebo up to 12 weeks), infections were reported in 28.7% of subjects treated with COSENTYX compared with 18.9% of subjects treated with placebo. Serious infections occurred in 0.14% of patients treated with COSENTYX and in 0.3% of patients treated with placebo [see Warnings and Precautions (5.1)].
Over the entire treatment period (a total of 3430 plaque psoriasis subjects treated with COSENTYX for up to 52 weeks for the majority of subjects), infections were reported in 47.5% of subjects treated with COSENTYX (0.9 per patient-year of follow-up). Serious infections were reported in 1.2% of subjects treated with COSENTYX (0.015 per patient-year of follow-up).
Phase 3 data showed an increasing trend for some types of infection with increasing serum concentration of secukinumab. Candida infections, herpes viral infections, staphylococcal skin infections, and infections requiring treatment increased as serum concentration of secukinumab increased.
Neutropenia was observed in clinical trials. Most cases of secukinumab-associated neutropenia were transient and reversible. No serious infections were associated with cases of neutropenia.
Exacerbation of Crohn’s Disease
Exacerbations of Crohn’s disease, in some cases serious, were observed in clinical trials in both COSENTYX and placebo treated patients. In the psoriasis program, with 3430 patients exposed to COSENTYX there were 3 cases of exacerbation of Crohn’s disease [see Warnings and Precautions (5.3)].
Hypersensitivity Reactions
Anaphylaxis and cases of urticaria occurred in COSENTYX-treated patients in clinical trials [see Warnings and Precautions (5.4)].
6.2 Immunogenicity
As with all therapeutic proteins, there is the potential for immunogenicity. The immunogenicity of COSENTYX was evaluated using an electrochemiluminescence-based bridging immunoassay. Less than 1% of subjects treated with COSENTYX developed antibodies to secukinumab in up to 52 weeks of treatment. However, this assay has limitations in detecting anti-secukinumab antibodies in the presence of secukinumab; therefore the incidence of antibody development might not have been reliably determined. Of the subjects who developed antidrug antibodies, approximately one-half had antibodies that were classified as neutralizing. Neutralizing antibodies were not associated with loss of efficacy.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to COSENTYX with the incidences of antibodies to other products may be misleading.
7 DRUG INTERACTIONS
Drug interaction trials have not been conducted with COSENTYX.
7.1 Live Vaccines
Patients treated with COSENTYX may not receive live vaccinations [see Warnings and Precautions (5.6)].
7.2 Non-Live Vaccines
Patients treated with COSENTYX may receive non-live vaccinations. Healthy individuals who received a single 150 mg dose of COSENTYX 2 weeks prior to vaccination with a non-U.S. approved group C meningococcal polysaccharide conjugate vaccine and a non-U.S. approved inactivated seasonal influenza vaccine had similar antibody responses compared to individuals who did not receive COSENTYX prior to vaccination. The clinical effectiveness of meningococcal and influenza vaccines has not been assessed in patients undergoing treatment with COSENTYX [see Warnings and Precautions (5.6)].
7.3 CYP450 Substrates
A role for IL-17A in the regulation of CYP450 enzymes has not been reported. The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation. Thus, COSENTYX, an antagonist of IL-17A, could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category B
There are no adequate and well controlled trials of COSENTYX in pregnant women. Developmental toxicity studies conducted with monkeys found no evidence of harm to the fetus due to secukinumab. COSENTYX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
An embryofetal development study was performed in cynomolgus monkeys with secukinumab. No malformations or embryofetal toxicity were observed in fetuses from pregnant monkeys that were administered secukinumab weekly by the subcutaneous route during the period of organogenesis at doses up to 30 times the maximum recommended human dose (MRHD; on a mg/kg basis at a maternal dose of 150 mg/kg).
A pre- and postnatal development toxicity study was performed in mice with a murine analog of secukinumab. No treatment related effects on functional, morphological or immunological development were observed in fetuses from pregnant mice that were administered the murine analog of secukinumab on gestation days 6, 11, and 17 and on postpartum days 4, 10, and 16 at doses up to 150 mg/kg/dose.
8.3 Nursing Mothers
It is not known whether secukinumab is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, caution should be exercised when COSENTYX is administered to a nursing woman.
8.4 Pediatric Use
Safety and effectiveness of COSENTYX in pediatric patients have not been evaluated.
8.5 Geriatric Use
Of the 3430 plaque psoriasis subjects exposed to COSENTYX in clinical trials, a total of 230 were 65 years or older, and 32 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 years and older was not sufficient to determine whether they responded differently from younger subjects.
10 OVERDOSAGE
Doses up to 30 mg/kg intravenously (i.e., approximately 2000 to 3000 mg) have been administered in clinical trials without dose-limiting toxicity. In the event of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
11 DESCRIPTION
Secukinumab is a recombinant human monoclonal IgG1/κ antibody that binds specifically to IL-17A. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.
COSENTYX Injection
COSENTYX injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. COSENTYX is supplied in a single-use Sensoready pen with a 27 gauge fixed ½ inch needle, or a single-use prefilled syringe with a 27 gauge fixed ½ inch needle. The removable cap of the COSENTYX Sensoready pen or prefilled syringe contains natural rubber latex.
Each COSENTYX Sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.
COSENTYX for Injection
COSENTYX for injection is supplied as a sterile, preservative free, white to slightly yellow, lyophilized powder in single-use vials. Each COSENTYX vial contains 150 mg of secukinumab formulated in L-histidine/L-histidine hydrochloride monohydrate (4.656 mg), polysorbate 80 (0.6 mg), and sucrose (92.43 mg). Following reconstitution with 1 mL Sterile Water for Injection, USP, the resulting pH is approximately 5.8.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.
12.2 Pharmacodynamics
Elevated levels of IL-17A are found in psoriatic plaques. Treatment with COSENTYX may reduce epidermal neutrophils and IL-17A levels in psoriatic plaques. Serum levels of total IL-17A (free and secukinumab-bound IL-17A) measured at Week 4 and Week 12 were increased following secukinumab treatment. These pharmacodynamic activities are based on small exploratory studies. The relationship between these pharmacodynamic activities and the mechanism(s) by which secukinumab exerts its clinical effects is unknown.
12.3 Pharmacokinetics
Absorption
Following a single subcutaneous dose of either 150 mg (one-half the recommended dose) or 300 mg in plaque psoriasis patients, secukinumab reached peak mean (± SD) serum concentrations (Cmax) of 13.7 ± 4.8 mcg/mL and 27.3 ± 9.5 mcg/mL, respectively, by approximately 6 days post dose.
Following multiple subcutaneous doses of secukinumab, the mean (± SD) serum trough concentrations of secukinumab ranged from 22.8 ± 10.2 mcg/mL (150 mg) to 45.4 ± 21.2 mcg/mL (300 mg) at Week 12. At the 300 mg dose at Week 4 and Week 12, the mean trough concentrations resulted from the Sensoready pen were 23% to 30% higher than those from the lyophilized powder and 23% to 26% higher than those from the prefilled syringe based on cross-study comparisons.
Steady-state concentrations of secukinumab were achieved by Week 24 following the every 4 week dosing regimens. The mean (± SD) steady-state trough concentrations ranged from 16.7 ± 8.2 mcg/mL (150 mg) to 34.4 ± 16.6 mcg/mL (300 mg).
In healthy subjects and subjects with plaque psoriasis, secukinumab bioavailability ranged from 55% to 77% following subcutaneous dose of 150 mg (one-half the recommended dose) or 300 mg.
Distribution
The mean volume of distribution during the terminal phase (Vz) following a single intravenous administration ranged from 7.10 to 8.60 L in plaque psoriasis patients. Intravenous use is not recommended [see Dosage and Administration (2)].
Secukinumab concentrations in interstitial fluid in lesional and non-lesional skin of plaque psoriasis patients ranged from 27% to 40% of those in serum at 1 and 2 weeks after a single subcutaneous dose of secukinumab 300 mg.
Elimination
The metabolic pathway of secukinumab has not been characterized. As a human IgG1κ monoclonal antibody secukinumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
The mean systemic clearance (CL) ranged from 0.14 L/day to 0.22 L/day and the mean half-life ranged from 22 to 31 days in plaque psoriasis subjects following intravenous and subcutaneous administration across all psoriasis trials. Intravenous use is not recommended [see Dosage and Administration (2)].
Dose Linearity
Secukinumab exhibited dose-proportional pharmacokinetics in subjects with psoriasis over a dose range from 25 mg (approximately 0.083 times the recommended dose) to 300 mg following subcutaneous administrations.
Weight
Secukinumab clearance and volume of distribution increase as body weight increases.
Specific Populations
Hepatic or Renal Impairment:
No formal trial of the effect of hepatic or renal impairment on the pharmacokinetics of secukinumab was conducted.
Age: Geriatric Population:
Population pharmacokinetic analysis indicated that the clearance of secukinumab was not significantly influenced by age in adult subjects with plaque psoriasis. Subjects who are 65 years or older had apparent clearance of secukinumab similar to subjects less than 65 years old.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of COSENTYX. Some published literature suggests that IL-17A directly promotes cancer cell invasion in vitro, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown.
No effects on fertility were observed in male and female mice that were administered a murine analog of secukinumab at subcutaneous doses up to 150 mg/kg once weekly prior to and during the mating period.
14 CLINICAL STUDIES
Four multicenter, randomized, double-blind, placebo-controlled trials (Trials 1, 2, 3, and 4) enrolled 2403 subjects (691 randomized to COSENTYX 300 mg, 692 to COSENTYX 150 mg, 694 to placebo, and 323 to a biologic active control) 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, and Psoriasis Area and Severity Index (PASI) score greater than or equal to 12, and who were candidates for phototherapy or systemic therapy.
•Trial 1 enrolled 738 subjects (245 randomized to COSENTYX 300 mg, 245 to COSENTYX 150 mg, and 248 to placebo). Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks. Subjects randomized to COSENTYX received 300 mg or 150 mg doses at Weeks 0, 1, 2, 3, and 4 followed by the same dose every 4 weeks. Subjects randomized to receive placebo that were non-responders at Week 12 were then crossed over to receive COSENTYX (either 300 mg or 150 mg) at Weeks 12, 13, 14, 15, and 16 followed by the same dose every 4 weeks. All subjects were followed for up to 52 weeks following first administration of study treatment.
•Trial 2 enrolled 1306 subjects (327 randomized to COSENTYX 300 mg, 327 to COSENTYX 150 mg, 326 to placebo and 323 to a biologic active control). COSENTYX and placebo data are described. Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks. Subjects randomized to COSENTYX received 300 mg or 150 mg doses at Weeks 0, 1, 2, 3, and 4 followed by the same dose every 4 weeks. Subjects randomized to receive placebo that were non-responders at Week 12 then crossed over to receive COSENTYX (either 300 mg or 150 mg) at Weeks 12, 13, 14, 15, and 16 followed by the same dose every 4 weeks. All subjects were followed for up to 52 weeks following first administration of study treatment.
•Trial 3 enrolled 177 subjects (59 randomized to COSENTYX 300 mg, 59 to COSENTYX 150 mg, and 59 to placebo) and assessed safety, tolerability, and usability of COSENTYX self-administration via prefilled syringe for 12 weeks. Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3, and 4, followed by the same dose every 4 weeks for up to 12 weeks total.
•Trial 4 enrolled 182 subjects (60 randomized to COSENTYX 300 mg, 61 to COSENTYX 150 mg, and 61 to placebo) and assessed safety, tolerability, and usability of COSENTYX self-administration via Sensoready pen for 12 weeks. Subjects received subcutaneous treatment at Weeks 0, 1, 2, 3, and 4, followed by the same dose every 4 weeks for up to 12 weeks total.
Endpoints
In all trials, the endpoints were the proportion of subjects who achieved a reduction in PASI score of at least 75% (PASI 75) from baseline to Week 12 and treatment success (clear or almost clear) on the Investigator’s Global Assessment modified 2011 (IGA). Other evaluated outcomes included the proportion of subjects who achieved a reduction in PASI score of at least 90% (PASI 90) from baseline at Week 12, maintenance of efficacy to Week 52, and improvements in itching, pain and scaling at Week 12 based on the Psoriasis Symptom Diary©.
The PASI is a composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes within the affected regions (induration, erythema and scaling). The IGA is a 5-category scale including “0 = clear” “1 = almost clear”, “2 = mild”, “3 = moderate” or “4 = severe” indicating the physician’s overall assessment of the psoriasis severity focusing on induration, erythema and scaling. Treatment success of “clear” or “almost clear” consisted of no signs of psoriasis or normal to pink coloration of lesions, no thickening of the plaque and none to minimal focal scaling.
Baseline Characteristics
Across all treatment groups the baseline PASI score ranged from 11 to 72 with a median of 20 and the baseline IGA score ranged from “moderate” (62%) to “severe” (38%). Of the 2077 plaque psoriasis subjects who were included in the placebo-controlled trials, 79% were biologic-naïve (have never received a prior treatment with biologics) and 45% were non-biologic failures (failed to respond to a prior treatment with non-biologics therapies). Of the patients who received a prior treatment with biologics, over one-third were biologic failures. Approximately 15% to 25% of trial subjects had a history of psoriatic arthritis.
Clinical Response
The results of Trials 1 and 2 are presented in Table 2.
Table 2 Clinical Outcomes at Week 12 in Adults with Plaque Psoriasis in Trials 1 and 2

Trial 1 Trial 2
COSENTYX
300 mg
(N=245)
n (%)
COSENTYX
150 mg
(N=245)
n (%)
Placebo
(N=248)
n (%)
COSENTYX
300 mg
(N=327)
n (%)
COSENTYX
150 mg
(N=327)
n (%)
Placebo
(N=326)
n (%)
PASI 75 response 200 (82) 174 (71) 11 (4) 249 (76) 219 (67) 16 (5)
IGA of clear or almost clear 160 (65) 125 (51) 6 (2) 202 (62) 167 (51) 9 (3)
The results of Trials 3 and 4 are presented in Table 3.
Table 3 Clinical Outcomes at Week 12 in Adults with Plaque Psoriasis in Trials 3 and 4

Trial 3 Trial 4
COSENTYX
300 mg
(N=59)
n (%)
COSENTYX
150 mg
(N=59)
n (%)
Placebo
(N=59)
n (%)
COSENTYX
300 mg
(N=60)
n (%)
COSENTYX
150 mg
(N=61)
n (%)
Placebo
(N=61)
n (%)
PASI 75 response 44 (75) 41 (69) 0 (0) 52 (87) 43 (70) 2 (3)
IGA of clear or almost clear 40 (68) 31 (53) 0 (0) 44 (73) 32 (52) 0 (0)
Examination of age, gender, and race subgroups did not identify differences in response to COSENTYX among these subgroups. Based on post-hoc sub-group analyses in patients with moderate to severe psoriasis, patients with lower body weight and lower disease severity may achieve an acceptable response with COSENTYX 150 mg.
PASI 90 response at Week 12 was achieved with COSENTYX 300 mg and 150 mg compared to placebo in 59% (145/245) and 39% (95/245) versus 1% (3/248) of subjects, respectively (Trial 1) and 54% (175/327) and 42% (137/327) versus 2% (5/326) of subjects, respectively (Trial 2). Similar results were seen in Trials 3 and 4.
With continued treatment over 52 weeks, subjects in Trial 1 who were PASI 75 responders at Week 12 maintained their responses in 81% (161/200) of the subjects treated with COSENTYX 300 mg and in 72% (126/174) of subjects treated with COSENTYX 150 mg. Trial 1 subjects who were clear or almost clear on the IGA at Week 12 also maintained their responses in 74% (119/160) of subjects treated with COSENTYX 300 mg and in 59% (74/125) of subjects treated with COSENTYX 150 mg. Similarly in Trial 2, PASI 75 responders maintained their responses in 84% (210/249) of subjects treated with COSENTYX 300 mg and in 82% (180/219) of subjects treated with COSENTYX 150 mg. Trial 2 subjects who were clear or almost clear on the IGA also maintained their responses in 80% (161/202) of subjects treated with COSENTYX 300 mg and in 68% (113/167) of subjects treated with COSENTYX 150 mg.
Among the subjects who chose to participate (39%) in assessments of patient reported outcomes, improvements in signs and symptoms related to itching, pain, and scaling, at Week 12 compared to placebo (Trials 1 and 2) were observed using the Psoriasis Symptom Diary©.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
COSENTYX Sensoready pen:
•NDC 0078-0639-41: Carton of two 150 mg/mL (300 mg dose) Sensoready pens (injection)
•NDC 0078-0639-68: Carton of one 150 mg/mL single-use Sensoready pen (injection)
COSENTYX prefilled syringe:
•NDC 0078-0639-98: Carton of two 150 mg/mL (300 mg dose) single-use prefilled syringes (injection)
•NDC 0078-0639-97: Carton of one 150 mg/mL single-use prefilled syringe (injection)
The removable cap of the COSENTYX Sensoready pen and prefilled syringe contains natural rubber latex. Each Sensoready pen and prefilled syringe is equipped with a needle safety guard.
COSENTYX vial (for healthcare professional use only):
•NDC 0078-0657-61: Carton of one 150 mg lyophilized powder in a single-use vial (for injection)
16.2 Storage and Handling
COSENTYX Sensoready pens, prefilled syringes and vials must be refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Keep the product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming do not shake. COSENTYX does not contain a preservative; discard any unused portion.

诺华的Cosentyx(TM)被欧盟批准用于中、重度银屑病一线治疗
- Cosentyx 是可用于银屑病的一线全身治疗的唯一生物制剂,并且可代替其他具有显著副作用的治疗;所有其他生物制剂被推荐作为二线治疗。
- IIIb期 CLEAR 研究显示 Cosentyx优于优特克单抗 (ustekinumab)
- III期研究显示,≥70%接受 Cosentyx 300 mg 治疗的患者在治疗最初16周内皮损完全消除 (PASI 100) 或接近完全消除 (PASI 90)
-对银屑病患者而言,皮损消除是最终的治疗目标;50%的银屑病患者对现有治疗不满意。
2015年1月26日,诺华近日宣布,欧盟委员会(EC)批准 Cosentyx(secukinumab,曾用名AIN457)用于适合接受全身治疗的中、重度斑块型银屑病成年患者的一线全身治疗。
Cosentyx(剂量300mg)是首个也是唯一获得欧盟批准的白细胞介素-17A(IL-17A)抑制剂。这一批准标志着银屑病治疗的重要里程碑,为患者提供了一种新的重要一线生物制剂治疗选择。目前在欧洲,包括抗肿瘤坏死因子(抗TNF)药物和优特克单抗(ustekinumab) 在内的所有治疗银屑病的生物制剂均被推荐作为二线全身治疗。
诺华制药全球负责人David Epstein表示,“欧盟传来的好消息意味着银屑病患者将可能实现完全消除皮损的梦想。近半数的银屑病患者对包括生物制剂治疗在内的现有治疗并不满意,这说明患者的治疗需求还远未得到满足。作为银屑病一线全身治疗药物,Cosentyx将可提高患者皮损完全消除或接近完全消除的可能性。”
银屑病治疗的关键目标是皮损完全消除,皮肤恢复正常
临床研究显示;≥70%接受Cosentyx 300mg治疗的患者在治疗最初16周内皮损完全消除(PASI 100)或接近完全消除 (PASI 90) ,并且重要的是,大部分患者在继续接受治疗的情况下,皮损完全消除或接近完全消除的效果可维持至第52周。来自Cosentyx 临床试验的数据也显示,皮损完全消除或接近完全消除与银屑病患者的健康相关生活质量之间存在显著正相关。
欧盟的批准决定主要基于IIIb期CLEAR研究的最新结果,该研究显示Cosentyx在消除中、重度斑块型银屑病患者的皮肤方面优于优特克单抗。CLEAR研究是Cosentyx的第2项头对头研究。FIXTURE研究也显示,Cosentyx 在消除皮损方面优于依那西普6。III期临床试验显示,Cosentyx的总体安全性较好,并且在头对头研究中与依那西普和优特克单抗之间的差异非常小。
除了欧盟之外,Cosentyx还被澳大利亚批准用于治疗中、重度斑块型银屑病和被日本批准用于治疗中、重度斑块型银屑病和活动性银屑病关节炎 (PsA)。
2014年10月皮肤科和眼科药物咨询委员会(DODAC) 全体成员一致建议美国食品药品管理局(FDA)批准Cosentyx 用于治疗中、重度斑块型银屑病。
Cosentyx 尚未在中国获得批准。
关于Cosentyx(secukinumab)和白细胞介素-17A(IL-17A)
Cosentyx 是选择性白细胞介素-17A(IL-17A)的人类单克隆抗体。IL-17A在银屑病受累皮肤中的浓度较高,是试验性治疗的首选靶点。Cosentyx 通过抑制IL-17A的作用来发挥疗效。
III 期项目显示,Cosentyx的安全性较好,secukinumab 300mg治疗组和150mg治疗组的不良事件严重度和发生率相似。
有关使用Cosentyx 治疗掌跖银屑病、指甲银屑病和掌跖脓疱病的IIIb期银屑病研究正在进行中。
有关使用Cosentyx 治疗银屑病关节炎(PsA)和强直性脊柱炎(AS)的III期研究也正在进行中;计划在2015年向监管部门递交申请材料。
关于银屑病
银屑病是一种慢性免疫介导性疾病,其特征为厚且广泛的皮肤病变(称为斑块),伴有瘙痒、脱屑和疼痛;该病与生理和心理生活质量明显下降相关。银屑病大约累及全球3%的人口,全球患者总人数超过1.25亿。在欧洲,患病率估计为0.8%,意味着约370万欧洲人患有斑块型银屑病,约240万被认为患有中至重度疾病。
这一常见且令人困扰的疾病不仅仅是影响美观的问题 -甚至症状非常轻微的患者也每天处于困扰中。此外,由于高达50%的银屑病患者对包括生物制剂治疗在内的现有治疗并不满意,因此目前亟需治疗银屑病的新型药物。

责任编辑:admin


相关文章
cosentyx(Secukinumab)预装注射器/注射笔
Repatha(evolocumab)注射液/预装注射器
美国FDA批准Repatha注射剂为治疗胆固醇血症病的新药
Lemtrada(Alemtuzumab Injection for Intravenous Infusion)
二甲双胍片|Metformin(metformin filmcoated tablets)
伟素注射液|Vessel(Sulodexide Injection)
SUREPOST Tabs(Repaglinide)瑞格列奈片
Signifor LAR(帕瑞肽长效注射剂)
肢端肥大症长效药物Signifor LAR注射剂获欧盟批准
Plenaxis injectable(阿巴瑞克注射混悬液)
Endoxan(环磷酰胺原末[口服散装粉])
 

最新文章

更多

· ADEMPAS(RIOCIGUAT)TABL...
· RIXUBIS(Coagulation Fa...
· GLIADEL Wafer(Polifepr...
· 尼达尼布软胶囊|Ofev(ni...
· 碘克沙醇注射剂VISIPAQU...
· SAVAYSA(EDOXABAN TOSYL...
· VIEKIRA PAK(DASABUVIR...
· TECHNIVIE(ombitasvir, ...
· ODOMZO(sonidegib 原名L...
· OLYSIO(SIMEPREVIR SODI...

推荐文章

更多

· ADEMPAS(RIOCIGUAT)TABL...
· RIXUBIS(Coagulation Fa...
· GLIADEL Wafer(Polifepr...
· 尼达尼布软胶囊|Ofev(ni...
· 碘克沙醇注射剂VISIPAQU...
· SAVAYSA(EDOXABAN TOSYL...
· VIEKIRA PAK(DASABUVIR...
· TECHNIVIE(ombitasvir, ...
· ODOMZO(sonidegib 原名L...
· OLYSIO(SIMEPREVIR SODI...

热点文章

更多

· 尼达尼布软胶囊|Ofev(ni...
· GLIADEL Wafer(Polifepr...
· RIXUBIS(Coagulation Fa...
· ADEMPAS(RIOCIGUAT)TABL...